New prognostic markers of preeclampsia and anemia in obese pregnant women
AbstractThe aim of the study was to identify new prognostic markers of preeclampsia and anemia in obese women.
Material and methods. A prospective cohort study was conducted, which included 159 pregnant women at full–term gestation (37.0–41.0 weeks). The 1st group included pregnant women with obesity and preeclampsia (n=40), the 2nd – patients with anemia and obesity (n=39), the 3rd – obese women (n=42), the 4th – normal-weight pregnant women without a burdened somatic history (n=38). For protein quantification by mass spectrometry, a Normalised Spectral Adundance Factor (NSAF) was calculated for each identified protein.
Results. Among the identified proteomic spectrum, 8 proteins were identified, the differences in the spectral prevalence of which significantly differed from the control group. For pregnant women with obesity and PE, significant coefficients of change were identified for 4 protein molecules when comparing their spectral prevalence with those in obese patients: Immunoglobulin kappa variable 2D-28, Zinc-alpha-2-glycoprotein, Lumican, Apolipoprotein C-IV. However, the differences were statistically significant only for Zinc-alpha-2-glycoprotein. Keratin type II cytoskeletal 1 protein was significantly significant for a cohort of pregnant women with anemia and obesity.
Conclusion. The most promising serological marker for the prognosis of preeclampsia in obesity is Zincalpha-2-glycoprotein, for the prognosis of anemia in obesity – Keratin type II cytoskeletal 1. The results obtained demonstrate the need for additional studies to investigate the proteome of obese pregnant women.
Keywords:obesity; anemia; preeclampsia; mass spectrometry; proteomic analysis
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Orazmuradov A.A., Morozov S.G., Bekbaeva I.V., Zokirova N.M., Haddad Kh., Kyrtikov S.I., Mukovnikova E.V. New prognostic markers of preeclampsia and anemia in obese pregnant women. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2024; 12. Supplement: 20–4. DOI: https://doi.org/10.33029/2303-9698-2024-12-suppl-20-24 (in Russian)
REFERENCES
1. Seregina D.S., Nikolaenkov I.P., Kuz’minykh T.U. Obesity represents a strong pathogenetic link with the pathology of pregnancy and childbirth. Zhurnal akusherstva i zhenskikh bolezney [Journal of Obstetrics and Women’s Diseases]. 2020; 69 (2): 73–82. DOI: https://doi.org/10.17816/JOWD69273-82 (in Russian)
2. Anemia and reproductive health. In: V.E. Radzinsky (ed.). Moscow: Redaktsiya zhurnala StatusPraesens, 2019: 200 p. (in Russian)
3. Obesity. Diabetes. Pregnancy. Versions and contraversions. Clinical practices. Prospects. In: V.E. Radzinsky, T.L. Botasheva, O.V. Papysheva, et al.; V.E. Radzinsky, T.L. Botasheva, G.A. Kotaysh (eds). Moscow: GEOTAR-Media, 2020: 528 p. (in Russian)
4. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. 2020. URL: www.who.int/publications-detail/9789240000124
5. Malinowski A.K., Murji A. Iron deficiency and iron deficiency anemia in pregnancy. CMAJ. 2021; 193 (29): E1137–8. DOI: https://doi.org/10.1503/cmaj.210007 PMID: 34312167; PMCID: PMC8321297.
6. Radzinsky V.E., Knyazev S.A., Kostin I.N., et al. Predictive obstetrics. Moscow: Redaktsiya zhurnala StatusPraesens, 2021: 520 p. (in Russian)
7. Frazer D.M., Anderson G.J. Ironing out the effects of overweight and obesity on hepcidin production during pregnancy. J Nutr. 2021; 151 (8): 2087–8. DOI: https://doi.org/10.1093/jn/nxab200
8. Papysheva O.V., Kotaysh G.A., Orazmuradov A.A., et al. Pregnancy complications in women with metabolic syndrome. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2018; 6 (3 suppl): 18–22. DOI: https://doi.org/10.24411/2303-9698-2018-13902 (in Russian)
9. Wang Zh., Zhao G., Zeng M., et al. Overview of extracellular vesicles in the pathogenesis of preeclampsia. Biol Reprod. 2021; 105 (1): 32–9. DOI: https://doi.org/10.1093/biolre/ioab060
10. Hassan M.I., Waheed A., Yadav S., et al. Zinc alpha 2-glycoprotein: a multidisciplinary protein. Mol Cancer Res. 2008; 6 (6): 892–906. DOI: https://doi.org/10.1158/1541-7786.MCR-07-2195
11. Alenad M., Alkaltham L.F., Sabico Sh., et al. Associations of zinc-α-2-glycoprotein with metabolic syndrome and its components among adult Arabs. Sci Rep. 2022; 12 (1): 4908. DOI: https://doi.org/10.1038/s41598-022-09022-1
12. Huang D., Mao X., Peng J., et al. Role of adipokine zinc-α2-glycoprotein in coronary heart disease. Am J Physiol Endocrinol Metab. 2019; 317 (6): E1055–62. DOI: https://doi.org/10.1152/ajpendo.00075.2019
13. Banaszak M., Górna I., Przysławski J. Zinc and the innovative zinc-α2-glycoprotein adipokine play an important role in lipid metabolism: a critical review. Nutrients. 2021; 13 (6): 2023. DOI: https://doi.org/10.3390/nu13062023